Physiomics, Sareum deal

Physiomics will use its SystemCell in silico technology to simulate the effects of cancer drugs in living systems with an undisclosed compound from Sareum's checkpoint kinase 1 (Chk1) inhibitor program in combination with Gemzar gemcitabine to treat pancreatic cancer. Financial terms were not disclosed. ...